Results 171 to 180 of about 4,590 (196)
Some of the next articles are maybe not open access.
Insulin Glargine: A New Basal Insulin
The Annals of Pharmacotherapy, 2002OBJECTIVE: To review the pharmacology, pharmacokinetics, dosing guidelines, adverse effects, drug interactions, and clinical efficacy of insulin glargine. DATA SOURCES: Primary and review articles regarding insulin glargine were identified by MEDLINE search (1966–July 2001); abstracts were identified through Institute for Scientific Information Web of ...
Danial E. Baker +3 more
openaire +3 more sources
Intentional overdose with insulin glargine [PDF]
American Journal of Health-System Pharmacy, 2009 Intentional and accidental insulin glargine overdose is extremely rare. Little is known about the pharmacodynamics of insulin glargine when taken as an overdose. We describe an insulin glargine overdose in a nondiabetic patient.
A. Anwar +4 more
openaire +1 more source
Intentional Overdose with Insulin Glargine and Insulin Aspart
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2004Reports of intentional massive overdoses of insulin are infrequent. A review of the literature revealed no reports of overdose attempts with either insulin glargine or insulin aspart. We report the case of a 33‐year‐old woman without diabetes mellitus who intentionally injected herself with an overdose of both products, which belonged to her husband ...
Toyin S. Tofade, E. Allen Liles
openaire +3 more sources
Insulin glargine: a basal insulin for the management of diabetes
Expert Review of Endocrinology & Metabolism, 2007The prevalence of diabetes mellitus has been increasing steadily in the last 30 years and it is predicted that there will be 300 million people affected by 2025. Insulin deficiency is a feature of both Type 1 and 2 diabetes; insulin treatment, obligatory in Type 1, will also be required in many Type 2 patients.
Laurence Kennedy, Cecilia Lansang
openaire +3 more sources
The Lancet, 2009
www.thelancet.com Vol 374 November 21, 2009 1743 LAA trauma may relate to the fi xation barbs. Too enthusiastic a tug on the device during stability testing may result in a pericardial eff usion requiring intervention. The paper reports that fi ve of 408 patients who had a device implanted had periprocedural strokes, and this was attributed by Holmes ...
Ralf Bender +3 more
openaire +2 more sources
www.thelancet.com Vol 374 November 21, 2009 1743 LAA trauma may relate to the fi xation barbs. Too enthusiastic a tug on the device during stability testing may result in a pericardial eff usion requiring intervention. The paper reports that fi ve of 408 patients who had a device implanted had periprocedural strokes, and this was attributed by Holmes ...
Ralf Bender +3 more
openaire +2 more sources
Medisch-Farmaceutische Mededelingen, 2004
Betrekkelijk kortgeleden is in Nederland insuline glargine in de handel gekomen. De langdurige werking daarvan berust op de vorming van subcutane insuline-microprecipitaten waaruit slechts heel geleidelijk insuline wordt vrijgemaakt.
openaire +2 more sources
Betrekkelijk kortgeleden is in Nederland insuline glargine in de handel gekomen. De langdurige werking daarvan berust op de vorming van subcutane insuline-microprecipitaten waaruit slechts heel geleidelijk insuline wordt vrijgemaakt.
openaire +2 more sources
Insulin glargine in enteric tube feeding
Diabetes Research and Clinical Practice, 2007Diabetes Res Clin Pract. 2007 Nov;78(2):298-9. Epub 2007 May 3. Insulin glargine in enteric tube feeding. Marchetti G, Tesauro M, Di Daniele N, Bollea MR, Lauro R, Bertoli A. Insulin glargine, a long-acting insulin analogue, was introduced to provide effective basal insulin replacement with once-daily dosing.
Marchetti, G +5 more
openaire +5 more sources
Unintentional overdose of insulin glargine
American Journal of Health-System Pharmacy, 2008Insulin glargine is a long-acting recombinant human insulin analogue administered once daily for use as basal insulin therapy. When subcutaneously injected, it exhibits a relatively flat blood-level-versus-time curve, with a peak response in 3 hours and a 24-hour duration of action.[1][1] We ...
Bryan R. Kuhn, Lee Cantrell
openaire +2 more sources
The First Interchangeable Biosimilar Insulin: Insulin Glargine-yfgn
Journal of Diabetes Science and Technology, 2021On March 23, 2020, all insulin products were reclassified as biologics instead of drugs under the Biological Price Competition and Innovation (BPCI) Act of 2009. This allows biosimilar insulin products to be manufactured when the patent expires for the reference biologic, sometimes called the originator or brand name product.
Mark C. Matli +5 more
openaire +2 more sources
Use of insulin glargine during pregnancy
Acta Obstetricia et Gynecologica Scandinavica, 2007AbstractBackground. Good metabolic control maintained throughout pregnancy reduces maternal and fetal complications in diabetic women. The long‐acting insulin analogue glargine has 24‐h persistence and a peakless action profile, and could contribute to more stable daily plasma glucose levels and improved glycemic control.
Risto Kaaja +4 more
openaire +3 more sources